Moreover, the VHL mutations are crucial for RCC pathogenesis, as VHL inactivation is associated with the upregulation of hypoxia-inducible factors (HIF1 and HIF2), playing a more pronounced role in activating downstream pathways, including EPO production [10]. This evidence concerns the gene EPO and renal cell carcinoma.